Longeveron Inc. (LGVN)
After hours:
| Previous close | 6.10 |
| Open | 6.13 |
| Bid | 0.00 x 1100 |
| Ask | 0.00 x 800 |
| Day's range | 5.89 - 6.41 |
| 52-week range | 2.84 - 45.00 |
| Volume | |
| Avg. volume | 159,416 |
| Market cap | 123.854M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Longeveron to Announce Second Quarter 2022 Financial Results on August 12, 2022
Live conference call on Friday, August 12 at 8:30 a.m. ESTMIAMI, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the Company will release its second quarter 2022 financial results on Friday, August 12, 2022 before the open of the U.S. financial markets. Management will host a conference call to discuss t
- GlobeNewswire
Longeveron Announces Abstract Accepted for Presentation at the Alzheimer’s Association International Conference (AAIC)
MIAMI, July 07, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, today announced an abstract regarding the Lomecel-B Phase 2a trial in Alzheimer’s Disease (AD) has been accepted for a poster presentation at the Alzheimer’s Association International Conference (AAIC), being held July 31-August 4, 2022 in San Diego, California, as well as virtually. “We are pleas
- GlobeNewswire
Longeveron Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results
Conference call scheduled for 8:30 a.m. ET todayMIAMI, May 13, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today provided a business update and reported its financial results for the first quarter ended March 31, 2022. First Quarter Business Updates: Lomecel-B for Alzheimer’s Disease: In January 2022, we initiated enrollment in a
